Published in PLoS One on April 03, 2014
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell (2008) 11.53
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell (2005) 8.37
IFNalpha activates dormant haematopoietic stem cells in vivo. Nature (2009) 7.17
Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity (2001) 5.14
Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell (2007) 5.14
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat Biotechnol (2011) 3.81
Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell (2010) 3.69
Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity (2002) 3.69
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A (2010) 3.41
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med (2002) 3.24
Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. J Exp Med (2010) 2.98
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A (1998) 2.79
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell (2013) 2.47
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood (2009) 2.41
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell (2012) 2.36
CD150- side population cells represent a functionally distinct population of long-term hematopoietic stem cells. Blood (2007) 2.27
Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A/E by bone marrow cells. Blood (1993) 2.19
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood (2005) 2.17
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood (2010) 2.16
Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. Blood (2002) 2.04
Hematopoietic stem cell heterogeneity takes center stage. Cell Stem Cell (2012) 1.94
Intermediate-term hematopoietic stem cells with extended but time-limited reconstitution potential. Cell Stem Cell (2010) 1.87
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood (2010) 1.81
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia (2007) 1.81
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med (2002) 1.77
Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol (2011) 1.76
CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. Blood (2013) 1.74
Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell (2012) 1.71
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
CD86 is expressed on murine hematopoietic stem cells and denotes lymphopoietic potential. Blood (2012) 1.65
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood (2012) 1.59
Janus kinase deregulation in leukemia and lymphoma. Immunity (2012) 1.52
Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood (2011) 1.48
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood (2013) 1.38
Stem cell heterogeneity: implications for aging and regenerative medicine. Blood (2012) 1.38
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
Lnk constrains myeloproliferative diseases in mice. J Clin Invest (2010) 1.29
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood (2013) 1.25
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood (2012) 1.13
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol (2009) 1.10
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood (2010) 0.99
Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech (2011) 0.98
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica (2011) 0.86
Generation of a new congenic mouse strain with enhanced chymase expression in mast cells. PLoS One (2013) 0.83
Separation of plasmacytoid dendritic cells from B-cell-biased lymphoid progenitor (BLP) and Pre-pro B cells using PDCA-1. PLoS One (2013) 0.83
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One (2014) 0.76